Infection and cancer: The case of hepatitis B

Journal of Clinical Oncology

Volumn 34, Issue 1, 2016, Pages 83-90

  Chan, Stephen L ^a   Wong, Vincent W S ^a   Qin, Shukui ^a,b   Chan, Henry L Y ^a,c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Special Administrative Region ^*  (China)

^c Bayi Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; VIRUS VACCINE;

ANTIVIRAL THERAPY; ASYMPTOMATIC DISEASE; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CHEMOEMBOLIZATION; CHRONIC HEPATITIS B; DISEASE SURVEILLANCE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPHYLAXIS; RADIOFREQUENCY ABLATION; RECURRENT DISEASE; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; VACCINATION; VIRUS LOAD; VIRUS REACTIVATION; NEOPLASMS; PHYSIOLOGY;

HEPATITIS B; HEPATITIS B VIRUS; HUMANS; NEOPLASMS; RISK FACTORS;

EID: 84954175072     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.5724     Document Type: Review

References (84)

1. de Martel C, Ferlay J, Franceschi S, et al: Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol 13:607-615, 2012
2. Bouvard V, Baan R, Straif K, et al: A review of human carcinogens: Part B. Biological agents. Lancet Oncol 10:321-322, 2009
3. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Biological agents: Volume 100 B. A reviewof human carcinogens. IARC Monogr Eval Carcinog Risks Hum 100:1-441, 2012
4. Parkin DM: The global health burden of infection-Associated cancers in the year 2002. Int J Cancer 118:3030-3044, 2006
5. Rodig SJ, Cheng J, Wardzala J, et al: Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest 122:4645-4653, 2012
6. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
7. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-2576, 2007
8. Feng H, Cheng AS, Tsang DP, et al: Cell cyclerelated kinase is a direct androgen receptor-regulated gene that drives beta-catenin/T cell factor-dependent hepatocarcinogenesis. J Clin Invest 121:3159-3175, 2011
9. Seeger C, Mason WS: Hepatitis B virus biology. Microbiol Mol Biol Rev 64:51-68, 2000
10. Liaw YF, Chu CM: Hepatitis B virus infection. Lancet 373:582-592, 2009
11. Ott JJ, Stevens GA, Groeger J, et al: Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30:2212-2219, 2012
12. Te HS, Jensen DM: Epidemiology of hepatitis B and C viruses: A global overview. Clin Liver Dis 14: 1-21, vii, 2010
13. Wong RJ, Cheung R, Ahmed A: Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patientswith hepatocellular carcinoma in the US. Hepatology 59:2188-2195, 2014
14. Marcellin P, Asselah T: Long-Term therapy for chronic hepatitis B: Hepatitis B virus DNA suppression leading to cirrhosis reversal. J Gastroenterol Hepatol 28:912-923, 2013
15. Yang HI, Lu SN, Liaw YF, et al: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 347:168-174, 2002
16. Chen CJ, Yang HI, Su J, et al: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65-73, 2006
17. Chan HL, Tse CH, Mo F, et al: High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 26:177-182, 2008
18. Chan HL, Wong GL, Tse CH, et al: Hepatitis B virus genotype C is associatedwith more severe liver fibrosis than genotype B. Clin Gastroenterol Hepatol 7:1361-1366, 2009
19. Wong GLH, Chan HLY, Yiu KKL, et al: Metaanalysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma. Aliment Pharmacol Ther 37:517-526, 2013
20. Kao JH, Chen PJ, Lai MY, et al: Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 124:327-334, 2003
21. Ni YH, Chang MH, Wu JF, et al: Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol 57:730-735, 2012
22. Chan HLY, Jia JD: Chronic hepatitis B in Asia: New insights from the past decade. J Gastroenterol Hepatol 26:131-137, 2011
23. Chien YC, Jan CF, Chiang CJ, et al: Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: A 20-year cohort study of 3.8 million vaccinees. Hepatology 60: 125-132, 2014
24. World Health Organization: Immunization, vaccines and biologicals: Hepatitis B. http://www. who.int/immunization/monitoring-surveillance/burden/vpd/surveillance-Type/passive/hepatitis/en/
25. Van Damme P, Leuridan E, Hendrickx G, et al: Should Europe have a universal hepatitis B vaccination programme? BMJ 347:f4057, 2013
26. Wu TW, Lin HHH, Wang LY: Chronic hepatitis B infection in adolescents who received primary infantile vaccination. Hepatology 57:38-45, 2013
27. Wu JN, Wen XZ, Zhou Y, et al: Impact of the free-vaccine policy on timely initiation and completion of hepatitis B vaccination in Fujian, China. J Viral Hepat 22:551-560, 2015
28. Ascherio A, Zhang SM, Hernan MA, et al: Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 344:327-332, 2001
29. Sung JJ, Tsoi KK, Wong VW, et al: Metaanalysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 28:1067-1077, 2008
30. Cooksley WG, Piratvisuth T, Lee SD, et al: Peginterferon alpha-2a (40 kDa): An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10:298-305, 2003
31. Liaw YF, Jia JD, Chan HL, et al: Shorter durations and lower doses of peginterferon alfa-2a are associatedwith inferior hepatitisBe antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 54:1591-1599, 2011
32. Buster EH, Hansen BE, Lau GK, et al: Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferonalfa. Gastroenterology 137:2002-2009, 2009
33. Bonino F, Marcellin P, Lau GK, et al: Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 56:699-705, 2007
34. Chan HL, Thompson A, Martinot-Peignoux M, et al: Hepatitis B surface antigen quantification: Why and how to use it in 2011-A core group report. J Hepatol 55:1121-1131, 2011
35. Wong VW, Wong GL, Yan KK, et al: Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51:1945-1953, 2010
36. Lucifora J, Xia Y, Reisinger F, et al: Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343:1221-1228, 2014
37. Liaw YF, Sung JJ, Chow WC, et al: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521-1531, 2004
38. Trepo C, Chan HL, Lok A: Hepatitis B virus infection. Lancet 384:2053-2063, 2014
39. Wong GL, Chan HL, Mak CW, et al: Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 58:1537-1547, 2013
40. Wu CY, Lin JT, Ho HJ, et al: Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: A nationwide cohort study. Gastroenterology 147:143.e5-151.e5, 2014
41. Kumada T, Toyoda H, Tada T, et al: Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: A propensity score analysis. J Hepatol 58:427-433, 2013
42. Hosaka T, Suzuki F, Kobayashi M, et al: Longterm entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58:98-107, 2013
43. Kim GA, Lim YS, An J, et al: HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: Clinical outcomes and durability. Gut 63:1325-1332, 2014
44. Papatheodoridis GV, Chan HL, Hansen BE, et al: Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy. J Hepatol 62:956-967, 2015
45. Wong GL, Chan HL, Chan HY, et al: Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology 144: 933-944, 2013
46. Arends P, Sonneveld MJ, Zoutendijk R, et al: Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: Limited role for risk scores in Caucasians. Gut doi: 10.1136/gutjnl-2014-307023 [epub ahead of print July 10, 2014]
47. Zhang BH, Yang BH, Tang ZY: Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130:417-422, 2004
48. Wong GL, Wong VW, Tan GM, et al: Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int 28:79-87, 2008
49. Feng K, Yan J, Li X, et al: A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 57:794-802, 2012
50. Koda M, Murawaki Y, Mitsuda A, et al: Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: A randomized control study. Cancer 92: 1516-1524, 2001
51. Sun AX, Cheng ZL, Wu PP, et al: Clinical outcome of medium-sized hepatocellular carcinoma treated with microwave ablation. World J Gastroenterol 21:2997-3004, 2015
52. Narayanan G, Froud T, Suthar R, et al: Irreversible electroporation of hepatic malignancy. Semin Intervent Radiol 30:67-73, 2013
53. Bruix J, Sherman M: Management of hepatocellular carcinoma: An update. Hepatology 53: 1020-1022, 2011
54. Wong GL, Chan HL, Tse YK, et al: Ontreatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology 59:986-995, 2014
55. Wong VW, Chan SL, Mo F, et al: Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 28: 1660-1665, 2010
56. Yuen MF, Tanaka Y, Fong DY, et al: Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 50:80-88, 2009
57. Yang HI, Yuen MF, Chan HL, et al: Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and validation of a predictive score. Lancet Oncol 12:568-574, 2011
58. Wong GL, Chan HL, Wong CK, et al: Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol 60:339-345, 2014
59. Chan HL, Wong GL, Choi PC, et al: Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 16:36-44, 2009
60. Jung KS, Kim SU, Ahn SH, et al: Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 53:885-894, 2011
61. Yeo W, Johnson PJ: Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43:209-220, 2006
62. Lok AS, Liang RH, Chiu EK, et al: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: Report of a prospective study. Gastroenterology 100:182-188, 1991
63. Yeo W, Chan PK, Zhong S, et al: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 62:299-307, 2000
64. Yeo W, Lam KC, Zee B, et al: Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 15: 1661-1666, 2004
65. Peng JW, Lin GN, Xiao JJ, et al: Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy. Asia Pac J Clin Oncol 8: 356-361, 2012
66. Lao XM, Wang D, Shi M, et al: Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma. Hepatol Res 41:553-563, 2011
67. Dan JQ, Zhang YJ, Huang JT, et al: Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: A retrospective study. Eur J Surg Oncol 39:865-872, 2013
68. Chan SL, Yeo W: Targeted therapy of hepatocellular carcinoma: Present and future. J Gastroenterol Hepatol 27:862-872, 2012
69. Zhu AX, Kudo M, Assenat E, et al: Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: The EVOLVE-1 randomized clinical trial. JAMA 312:57-67, 2014
70. Yeo W, Mok TS, Zee B, et al: A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97: 1532-1538, 2005
71. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57:167-185, 2012
72. Liaw YF, Leung N, Kao JH, et al: Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol Int 2:263-283, 2008
73. Lok AS, McMahon BJ: Chronic hepatitis B: Update 2009. Hepatology 50:661-662, 2009
74. Chan SL, Mo FK, Wong VW, et al: Use of antiviral therapy in surveillance: Impact on outcome of hepatitis B-related hepatocellular carcinoma. Liver Int 32:271-278, 2012
75. Poon RT, Fan ST, Lo CM, et al: Long-Term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: Implications for a strategy of salvage transplantation. Ann Surg 235:373-382, 2002
76. Adachi E, Maeda T, Matsumata T, et al: Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 108: 768-775, 1995
77. Kim BK, Park JY, Kim do Y, et al: Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int 28:393-401, 2008
78. Kubo S, Hirohashi K, Tanaka H, et al: Virologic and biochemical changes and prognosis after liver resection for hepatitis B virus-related hepatocellular carcinoma. Dig Surg 18:26-33, 2001
79. Yin J, Li N, Han Y, et al: Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: A two-stage longitudinal clinical study. J Clin Oncol 31:3647-3655, 2013
80. Chong CC, Wong GL, Wong VW, et al: Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: A prospective-retrospective study. Aliment Pharmacol Ther 41:199-208, 2015
81. Wong JS, Wong GL, Tsoi KK, et al: Metaanalysis: The efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 33:1104-1112, 2011
82. Chan SL: Drug development for hepatocellular carcinoma: Knowing the past helps to understand the future. Oncologist 19:1115-1117, 2014
83. Shao YY, Shau WY, Chan SY, et al: Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-Analysis of randomized clinical trials. Oncology doi: 10.1159/000369559 [epub ahead of print January 7, 2015]
84. Huynh H, Hao HX, Chan SL, et al: Loss of tuberous sclerosis complex 2 (TSC2) is frequent in hepatocellular carcinoma and predicts response to mTORC1 inhibitor everolimus. Mol Cancer Ther 14: 1224-1235, 2015